Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8261-8270 Newer>

Pharmaceutical Executive February 1, 2012 Jennifer Ringler	Industry Trees are Falling, But is FDA Around to Hear? Experts weigh in on FDA's long-awaited social media guidelines.
Pharmaceutical Executive February 1, 2012 Gulezian & Ashekian	How to Choose a Medical Animator For a rendering to be effective, the right balance must be struck between captivating art and accurate science. We propose some basic guidelines for pharma brand managers in search of an effective medical animation firm.
Pharmaceutical Executive February 1, 2012	Industry/Gov't R&D Support: So Far So Good The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.
Pharmaceutical Executive February 1, 2012 Engelmann & Geetter	Tightening the Compliance Net A dissection of the new Sunshine regulations in the Affordable Care Act
Pharmaceutical Executive February 1, 2012	Brazil Report: A Bold Player Blooms Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now.
Chemistry World February 3, 2012 Rebecca Trager	Whistleblowers accuse FDA of spying, persecution The US Food and Drug Administration is being sued by its own scientists and doctors who allege they were spied on and persecuted by the agency for expressing safety concerns about the approval of medical devices.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Chemistry World February 2012	Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
Chemistry World January 23, 2012 James Urquhart	Simple One Stop Shop for Difluoromethylation A new process developed by researchers opens the way for adding difluoromethyl (CF 2H) groups to drugs and agrochemicals in order to enhance their properties.
<Older 8261-8270 Newer> Return to current articles.